Drug maker also launches generic Azor in U.S.

JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has expanded its antihypertensive portfolio with the rollout of two new generic products in the United States.

Teva said this week that it’s in the final stages of launch preparation for olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets, a generic version of Tribenzor tablets from Daiichi Sankyo.

In addition, Teva has released amlodipine and olmesartan medoxomil tablets, a generic version of Azor tablets, also from Daiichi Sankyo, in the U.S.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and heart attacks, and many patients need more than one drug to achieve their blood pressure goals, Teva noted.

Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of an angiotensin II receptor blocker, a dihydropyridine calcium channel blocker and a thiazide diuretic to lower blood pressure. Amlodipine and olmesartan medoxomil tablets are a dihydropyridine calcium channel blocker and angiotensin II receptor blocker combination product indicated for the treatment of hypertension, alone or with other antihypertensive agents, to reduce blood pressure.

For the 12 months through August, U.S. sales totaled about $240 million for Tribenzor and $354.1 million for Azor, according to IMS Health data reported by Teva.